Patient-Reported Outcomes and Health-Related Quality of Life Following Radiotherapy for Bladder Cancer

S E Appleyard; A D Nikapota

doi:10.1016/j.clon.2021.03.016

Patient-Reported Outcomes and Health-Related Quality of Life Following Radiotherapy for Bladder Cancer

Clin Oncol (R Coll Radiol). 2021 Jun;33(6):400-406. doi: 10.1016/j.clon.2021.03.016.

Authors

S E Appleyard¹, A D Nikapota²

Affiliations

¹ Sussex Cancer Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.
² Sussex Cancer Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK. Electronic address: Ashok.nikapota@nhs.net.

PMID: 33863616
DOI: 10.1016/j.clon.2021.03.016

Abstract

Bladder cancer is the 11th most common cancer in the UK and with an ageing population the incidence is increasing. There is a relative lack of prospective quality of life (QoL) data evaluating the impact of the illness and treatment on QoL and patient-reported outcomes (PROs). Here we evaluate the available tools to assess QoL and PROs, and summarise the published data evaluating outcomes in patients treated with radiotherapy for muscle-invasive disease. We also discuss some of the recently completed studies and those ongoing that will help to shape future care and assist in decision making for patients and their clinicians.

Keywords: Bladder cancer; patient-reported outcomes; quality of life; radiotherapy.

MeSH terms

Humans
Longitudinal Studies
Patient Reported Outcome Measures
Quality of Life*
Urinary Bladder Neoplasms* / radiotherapy